Actively Recruiting
A Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients With GPC3-positive Advanced Solid Tumors
Led by Aptamer Sciences, Inc. · Updated on 2026-03-27
70
Participants Needed
4
Research Sites
163 weeks
Total Duration
On this page
Sponsors
A
Aptamer Sciences, Inc.
Lead Sponsor
C
CHA University
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is the first in human trial clinical study of AST-201 in patients with GPC3-positive advanced solid tumors. This study aims to evaluate the safety, tolerability, pharmacokinetic properties, and preliminary efficacy of AST-201 across various tumor types.
CONDITIONS
Official Title
A Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients With GPC3-positive Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male and female aged 6519 years
- Histologically and/or cytologically diagnosed with advanced recurrent solid tumor
- GPC3-positive confirmed by immunohistochemistry (IHC) test
- At least one measurable or evaluable lesion as per RECIST v1.1 or modified RECIST for hepatocellular carcinoma
- ECOG performance status of 0 or 1
- Life expectancy of at least 12 weeks
- Adequate blood, liver, kidney, and heart/coagulation function
- Child-Pugh Class A for hepatocellular carcinoma
You will not qualify if you...
- History of ischemic heart disease
- Anti-tumor treatment within the last 4 weeks
- Comorbid conditions such as uncontrolled hypertension or heart failure
- Pregnant, potentially pregnant, or breastfeeding women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
National Cancer Center, Korea
Goyang-si, Gyeonggi-do, South Korea, 10408
Actively Recruiting
2
CHA Bundang Medical Center
Seongnam, South Korea, 13609
Actively Recruiting
3
Severance Hospital
Seoul, South Korea, 03722
Actively Recruiting
4
Samsung Medical Center
Seoul, South Korea, 06351
Actively Recruiting
Research Team
A
Aptamer Sciences Inc.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here